Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors-Literature Review and Statement of Experts from Polish Dermatological Society

• Published in: Vaccines (Basel) Vol. 12; no. 1; p. 82
• Main Authors: Narbutt, Joanna, Żuber, Zbigniew, Lesiak, Aleksandra, Bień, Natalia, Szepietowski, Jacek C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-01-2024; MDPI
• Subjects: Analysis; Antibodies; biological drugs; Biological products; biologics; Chronic illnesses; COVID-19 vaccines; Deactivation; Dermatitis; Dermatology; Drug dosages; Drugs; Evaluation; Herpes viruses; Immune response; Immune system; immunization; Immunomodulation; Immunosuppressive agents; Immunotherapy; Infections; Infectious diseases; Inhibitors; JAK inhibitors; Kinases; Literature reviews; Medical research; Medicine, Experimental; mRNA vaccines; Physicians; Psoriasis; Psoriatic arthritis; Review; Rheumatology; Side effects; Standardization; Steroids; Therapy; TNF inhibitors; vaccination; vaccine; Vaccines; Viral infections; Germany; biological drugs; vaccine; biologics; immunization; JAK inhibitors; vaccination
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12010082

The growing use of biological drugs in immune-mediated chronic diseases has undoubtedly revolutionized their treatment. Yet, the topic of vaccinations in this group of patients still raises many concerns and implies many therapeutic problems that require discussion and standardization of management. The aim of this literature review is to present current knowledge regarding safety and efficacy of vaccinations in dermatological and rheumatological patients treated with biological drugs and JAK inhibitors. Additionally, this article provides recommendation from experts of the Polish Dermatological Society about proper use of vaccinations during therapy with biologics. Generally, all live attenuated vaccines are contraindicated during immunosuppressive/immunomodulatory therapy. If there is need, they should be administered long enough prior to the therapy or after cessation. Yet, inactivated vaccines mostly can be safely used, but the problem in this case is the effectiveness of the vaccination. Most studies report that the immune response in patients on biologics after administration of different inactivated vaccines is similar to or even better than in the control group. Thus, the importance of vaccination among patients on biologics must be emphasized to reduce omissions and the fear of possible side effects or insufficient post-vaccination response.